hb1801
Showing 1 - 2 of 2
Locally Advanced or Metastatic NSCLC Trial (HB1801, Taxotere)
Not yet recruiting
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- HB1801
- Taxotere
- (no location specified)
May 8, 2023
First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer Trial (KN026, HB1801, Pertuzumab)
Not yet recruiting
- First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
- KN026
- +4 more
- (no location specified)
Apr 20, 2023